Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma

Jaroslav Michalek, Darina Ocadlikova, Eva Matejkova, Veronika Foltankova, Silvie Dudová, Ondrej Slaby, Radek Horvath, Ludek Pour, Roman Hajek

. 2010 ; 148 (6) : 859-867. [pub] 20100113

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12026481

Grant support
NR8945 MZ0 CEP Register
1A8709 MZ0 CEP Register

Despite novel treatment strategies, multiple myeloma (MM) remains an incurable disease with low immunogenicity and multiple immune defects. We developed an ex vivo strategy for inducing myeloma-specific cytotoxic T lymphocytes (CTLs) and demonstrate the possibility of identification and long-term in vivo monitoring of individual myeloma-specific T-cell clones using the most sensitive clonotypic assay that is able to detect low frequencies of T-cell clones (1 clonotypic cell in 10(6) cells). Ten patients with MM were examined for the presence of tumour-reactive T cells using dendritic cells loaded with autologous tumour cells. All patients had detectable myeloma-reactive T cells in vitro. Expanded myeloma-reactive T cells demonstrated specific cytotoxic effects against autologous tumour cells in vitro (median 39.6% at an effector:target ratio of 40:1). The clonality of myeloma-specific T cells was studied with a clonotypic assay, which demonstrated both oligoclonal and monoclonal populations of myeloma-specific T cells. CD8(+) CTLs were the most immunodominant myeloma-specific T-cell clones and clinical responses were closely associated with the in vivo expansion and long-term persistence of individual CD8(+) T-cell clones, usually at very low frequencies (10(-3)-10(-6)). We conclude that the clonotypic assay is the most sensitive tool for immunomonitoring of low-frequency T cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12026481
003      
CZ-PrNML
005      
20140731114051.0
007      
ta
008      
120817e20100113xxk f 000 0#eng||
009      
AR
024    7_
$a 10.1111/j.1365-2141.2009.08034.x $2 doi
035    __
$a (PubMed)20067568
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Michálek, Jaroslav $7 xx0071617 $u University Cell Immunotherapy Centre, Masaryk University; Department of Paediatrics, University Hospital Brno, Brno, Czech Republic. jmichalek@fnbrno.cz
245    10
$a Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma / $c Jaroslav Michalek, Darina Ocadlikova, Eva Matejkova, Veronika Foltankova, Silvie Dudová, Ondrej Slaby, Radek Horvath, Ludek Pour, Roman Hajek
520    9_
$a Despite novel treatment strategies, multiple myeloma (MM) remains an incurable disease with low immunogenicity and multiple immune defects. We developed an ex vivo strategy for inducing myeloma-specific cytotoxic T lymphocytes (CTLs) and demonstrate the possibility of identification and long-term in vivo monitoring of individual myeloma-specific T-cell clones using the most sensitive clonotypic assay that is able to detect low frequencies of T-cell clones (1 clonotypic cell in 10(6) cells). Ten patients with MM were examined for the presence of tumour-reactive T cells using dendritic cells loaded with autologous tumour cells. All patients had detectable myeloma-reactive T cells in vitro. Expanded myeloma-reactive T cells demonstrated specific cytotoxic effects against autologous tumour cells in vitro (median 39.6% at an effector:target ratio of 40:1). The clonality of myeloma-specific T cells was studied with a clonotypic assay, which demonstrated both oligoclonal and monoclonal populations of myeloma-specific T cells. CD8(+) CTLs were the most immunodominant myeloma-specific T-cell clones and clinical responses were closely associated with the in vivo expansion and long-term persistence of individual CD8(+) T-cell clones, usually at very low frequencies (10(-3)-10(-6)). We conclude that the clonotypic assay is the most sensitive tool for immunomonitoring of low-frequency T cells.
650    _2
$a senioři $7 D000368
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a prezentace antigenu $x imunologie $7 D017951
650    _2
$a antigeny nádorové $x imunologie $7 D000951
650    _2
$a buněčná diferenciace $x imunologie $7 D002454
650    _2
$a buněčné klony $x imunologie $7 D002999
650    _2
$a hypervariabilní oblasti $x genetika $x imunologie $7 D022801
650    _2
$a cytotoxicita imunologická $x imunologie $7 D003602
650    _2
$a dendritické buňky $x imunologie $7 D003713
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a imunodominantní epitopy $x imunologie $7 D016056
650    _2
$a imunomagnetická separace $x metody $7 D018189
650    _2
$a aktivace lymfocytů $x imunologie $7 D008213
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a molekulární sekvence - údaje $7 D008969
650    _2
$a monitorování imunologické $x metody $7 D015166
650    _2
$a mnohočetný myelom $x imunologie $x terapie $7 D009101
650    _2
$a cytotoxické T-lymfocyty $x imunologie $7 D013602
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1#
$a Očadlíková, Darina. $7 xx0181164 $u University Cell Immunotherapy Centre, Masaryk University, Brno, Czech Republic
700    1_
$a Matějková, Eva $7 xx0139702 $u University Cell Immunotherapy Centre, Masaryk University, Brno, Czech Republic
700    1_
$a Foltánková, Veronika $7 xx0121909 $u University Cell Immunotherapy Centre, Masaryk University, Brno, Czech Republic
700    1_
$a Dudová, Silvie $7 xx0080377 $u Department of Internal Medicine, Division of Haemato-oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Slabý, Ondřej, $d 1981- $7 js20030220015 $u University Cell Immunotherapy Centre, Masaryk University, Brno, Czech Republic
700    1_
$a Horvath, Radek $u Department of Microbiology, Santa Anna University Hospital, Brno, Czech Republic
700    1_
$a Pour, Luděk $7 xx0102556 $u Department of Internal Medicine, Division of Haemato-oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Hájek, Roman, $d 1964- $7 nlk20000083645
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 148, č. 6 (20100113), s. 859-867
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20067568 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20140731114409 $b ABA008
999    __
$a ok $b bmc $g 948523 $s 783827
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 148 $c 6 $d 859-867 $e 20100113 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
GRA    __
$a NR8945 $p MZ0
GRA    __
$a 1A8709 $p MZ0
LZP    __
$a Pubmed-20120817/10/04
Back

Find record

Citation metrics

Archiving options